SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Eris Lifesciences - Quaterly Results

21 May 2026 Evaluate
The sales moved down -31.49% to Rs. 2773.10 millions for the March 2026 quarter as compared to Rs. 4047.70 millions during the corresponding quarter last year.The Net Loss for the quarter ended March 2026 is Rs. -86.00 millions as compared to Net Profit of Rs. 304.70 millions of corresponding quarter ended March 2025The company reported a degrowth in operating Profit to 487.50 millions from 1377.20 millions.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202603 202503 % Var 202603 202503 % Var 202603 202503 % Var
Sales 2773.10 4047.70 -31.49 18217.40 16977.50 7.30 18217.40 16977.50 7.30
Other Income 269.70 167.50 61.01 983.10 355.10 176.85 983.10 355.10 176.85
PBIDT 487.50 1377.20 -64.60 7106.40 5220.60 36.12 7106.40 5220.60 36.12
Interest 427.00 531.60 -19.68 1795.40 2202.40 -18.48 1795.40 2202.40 -18.48
PBDT 60.50 845.60 -92.85 5164.30 3018.20 71.11 5164.30 3018.20 71.11
Depreciation 388.20 433.80 -10.51 1543.80 1817.70 -15.07 1543.80 1817.70 -15.07
PBT -327.70 411.80 -179.58 3620.50 1200.50 201.58 3620.50 1200.50 201.58
TAX -241.70 107.10 -325.68 1180.00 426.60 176.61 1180.00 426.60 176.61
Deferred Tax -165.40 22.00 -851.82 570.40 206.80 175.82 570.40 206.80 175.82
PAT -86.00 304.70 -128.22 2440.50 773.90 215.35 2440.50 773.90 215.35
Equity 138.50 136.20 1.69 138.50 136.20 1.69 138.50 136.20 1.69
PBIDTM(%) 17.58 34.02 -48.33 39.01 30.75 26.86 39.01 30.75 26.86

Eris Lifesciences Share Price

1372.65 7.60 (0.56%)
09-Jun-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1779.40
Dr. Reddys Lab 1268.75
Cipla 1376.75
Zydus Lifesciences 1105.75
Lupin 2263.40
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×